CytomX Therapeutics Inc  

(Public, NASDAQ:CTMX)   Watch this stock  
Find more results for CTMX
14.76
+0.87 (6.26%)
After Hours: 14.76 0.00 (0.00%)
Aug 22, 4:27PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 13.96 - 14.89
52 week 9.85 - 20.02
Open 13.96
Vol / Avg. 260,494.00/215,842.00
Mkt cap 544.16M
P/E     -
Div/yield     -
EPS -1.70
Shares 36.87M
Beta     -
Inst. own 76%
Nov 1, 2017
Q3 2017 CytomX Therapeutics Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Aug 16, 2017
CytomX Therapeutics Inc at Wedbush PacGrow Healthcare Conference
Aug 7, 2017
Q2 2017 CytomX Therapeutics Inc Earnings Call - Webcast
Aug 7, 2017
Q2 2017 CytomX Therapeutics Inc Earnings Release
Jun 7, 2017
CytomX Therapeutics Inc at Jefferies Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -288.12% -391.54%
Operating margin -289.91% -396.10%
EBITD margin - -384.58%
Return on average assets -38.19% -29.72%
Return on average equity -160.51% -57.59%
Employees 78 -
CDP Score - -

Address

151 Oyster Point Blvd Ste 400
SOUTH SAN FRANCISCO, CA 94080-1910
United States - Map
+1-650-5153185 (Phone)
+1-650-3510353 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies. Its product candidates include CX-072, CX-2009, CX-2029, Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and CX-188. Its Probody platform utilizes active proteases in tumor tissue to allow monoclonal antibody-based therapies. Its investigational Probody therapeutics address clinically validated cancer targets in immuno-oncology, such as programmed death-ligand 1, against which CX-072 is directed, as well as targets, such as cluster of differentiation 166, against, which CX-2009 is directed.

Officers and directors

Hoyoung Huh Ph.D. Chairman of the Board
Age: 46
Bio & Compensation  - Reuters
Sean A McCarthy Ph.D. President, Chief Executive Officer, Director
Age: 48
Bio & Compensation  - Reuters
Debanjan Ray Chief Financial Officer, Principal Financial and Accounting Officer
Age: 39
Bio & Compensation  - Reuters
Cynthia Jane Ladd Senior Vice President, General Counsel
Age: 60
Bio & Compensation  - Reuters
W. Michael Kavanaugh M.D. Chief Scientific Officer and Head - Research and Non-Clinical Development
Age: 59
Bio & Compensation  - Reuters
Rachel W. Humphrey M.D. Chief Medical Officer
Age: 54
Bio & Compensation  - Reuters
Marion McCourt Director
Bio & Compensation  - Reuters
John A. Scarlett M.D. Director
Age: 66
Bio & Compensation  - Reuters
Neil Exter Independent Director
Bio & Compensation  - Reuters
Frederick Gluck Independent Director
Age: 80
Bio & Compensation  - Reuters